Subgroup analyses was done according to βeta-blocker use per breast cancer subtype (luminal, human epidermal growth factor receptor 2 (HER2)-positive or triple negative) and βeta-blocker class (nonselective or β1-selective). Here, ERBB2 is linked to breast carcinoma.